1World Health Organization.International society of hypertension guide lines for the management of hypertension,guidelines subcommittee.J Hypertens,1999,17(2):151-183.
2Kasiske BL,Vazquez MA,Hamon WE,et al.Recommendations for the outpatient surveillance of renal transplant recipients American society of transplantation.J Am Soc Nephrol,2000,11(Suppl 15):81-86.
8Brenner BM,Cooper ME,de Zeeuw D,et al.Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.New Engl Med,2001,345:861-869.
9Daholof B,Devercux RB,Kjddsen SE,et al.Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study(LIFE):a randomized trial against atenolol.Lancet,2002,359:995.
10Inigo P,Campistol JM,Saracho R,et al.Renoprotective effects of losartan in renal transplant recipients.Nephron Clin Pract,2003,95:73-74.
二级参考文献38
1Veenstra DL, Best JH, Hornberger J, et al. Incidence and long term cost of steroid related side effects after renal transplantation.Am J Kidney Dis,1999,33:829.
2Pirsch JD, Miller J, Deierhor MH, et al.A comparison of tacrolimus(FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation, 1997,63 : 977.
3Sander M,Lyson T,Thomas GD, et al . Sympathetic neural mechanisms of cyclosporine induced hypertension. Am J Hypertens1996, 9(S) : 121.
4Haas M, Mayer G. Cyclosporin A-associated hypertension-pathomechanisms and clinical consequences. Nephrol Dial Transplant, 1997,12:395.
5Taler SJ,Textor SC, Canzanello VJ, et al. Cyclosporine induced hypertension: Incidence, pathogenesis and management. Drug Saf, 1999,20:437.
6Shin GT, Khanna A, Ding R, et al. In vivo expression of transforming growth factor-betal in humans: stimulation by cyclosporine. Transplantation . 1998.65:313.
7Boots JMM, Christiaans M HL, van Duijnhoven EM, et al. Early steroid withdrawal in renal transplantation with tacrolimus dual therapy: a pilot study . Transplantation , 2002,74: 1 703.
8Vincenti F, Jensik SC, Filo RS, et al.A Long-term comparison of tacrolimus(FK506) and cyclosporine in kidney transplantation: Evidence for improved allograft survival at five years. Transplantation, 2002, 73:775.
9Margreiter R. Efficacy and safety of tacrolimus compared with cyclosporine microemulsion in renal transplantation: A randomized multicentre study, lancet, 2002,359: 741.
10Friemann S,Stopp K, Christ B, et al . Conversion to tacrolimus in hyperlipidemic patients.Transplant Proc, 1999,31 (S) :41.
1Paul LC,Benediktsson H. Post-transplant hypertension and chronic renal failure.Kidney Int, 1995,48 : 34-37.
2Easthope SE,Jarvis B. Candesartan cilexetil an update of its use in essential hypertension.Drugs, 2002,62 : 1253-1287.
3Brenner BM.Cooper ME,de Zeeuw D,et al.Effects of losartan on renal and cardiovascular outcomes in patients witll type 2 diabetes and nephropathy.New Engl Med, 2001,345 : 861-869.
